Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TLR2 | O60603 | 3/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | RRM1 | P23921 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25921498 | 0.90 | MEN1 (0.47) | MEN1KMT2ATLR2CNR1GLP1R | |
| SCHEMBL16350310 | 0.86 | MEN1 (0.53) | MEN1KMT2ATLR2CNR1GLP1R | |
| SCHEMBL8404637 | 0.86 | MEN1 (0.56) | MEN1KMT2ATLR2EPHX2THRB | |
| SCHEMBL25834708 | 0.86 | MEN1 (0.56) | MEN1KMT2ATLR2EPHX2THRB | |
| SCHEMBL25922160 | 0.85 | MEN1 (0.49) | MEN1KMT2ATLR2EPHX2CNR1 | |
| SCHEMBL25884905 | 0.85 | GLP1R (0.48) | EPHX2GLP1RCES2RRM1DPP7 | |
| SCHEMBL13857334 | 0.84 | MEN1 (0.54) | MEN1KMT2ACNR1MAPT | |
| SCHEMBL22861772 | 0.84 | MEN1 (0.54) | MEN1KMT2ATLR2CNR1MAPT | |
| SCHEMBL22837704 | 0.84 | MEN1 (0.58) | MEN1KMT2ATLR2EPHX2THRB | |
| SCHEMBL22856581 | 0.84 | MEN1 (0.58) | MEN1KMT2ATLR2EPHX2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | MEN1 4828/4885KMT2A 3122/4885TLR2 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.